NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...

In this study, we investigated the expression changes and interactions between miR4298 and lncKRTAP5-6-3 in chronically UVB-damaged human keratinocyte cell line (HaCaT) cells and explored miR4298-MAPK ...

This discrepancy indicates that the etching procedure introduced extraneous conductive pathways unrelated to the VHE, thereby explaining why a reduced band gap had been observed in prior ...